Onco-Innovations closes $1.2 million private placement financing

Onco-Innovations Limited (CBOE CA: ONCO) announced it closed a non-brokered private placement, issuing 1,870,000 units at $0.65 per unit for gross proceeds of $1,215,500.

Each unit consists of one common share and one warrant, with warrants exercisable at $0.75 per share for three years until March 12, 2029.

The Vancouver-based cancer research company stated the proceeds will fund general corporate and working capital purposes, including operational, research and development, and investor relations activities.

Onco-Innovations also issued 18,700 shares to a third party for administrative services related to the private placement. All securities are subject to a four-month statutory hold period under applicable securities laws.

The company holds an exclusive worldwide license to patented technology targeting solid tumors. The securities have not been registered under U.S. securities laws and cannot be offered or sold in the United States without registration or exemptions.

This private placement was previously announced on January 23, 2026, with an amendment disclosed February 12, 2026, according to the company's statement.

You May Also Be Interested In

• TD Cowen Downgrades Flowserve Corp. (FLS) to Hold
• Morgan Stanley Starts OGE Energy (OGE) at Equalweight
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight